Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph early_phase_1
1
50%
Ph phase_1
1
50%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 1Safety & dosage
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (50.0%)
Phase 11 (50.0%)

Trials by Status

recruiting150%
active_not_recruiting150%

Recent Activity

2 active trials
Showing 2 of 2
recruitingearly_phase_1

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

NCT07538128
active_not_recruitingphase_1

D2C7-IT With Atezolizumab for Recurrent Gliomas

NCT04160494

Clinical Trials (2)

Showing 2 of 2 trials
NCT07538128Early Phase 1

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Recruiting
NCT04160494Phase 1

D2C7-IT With Atezolizumab for Recurrent Gliomas

Active Not Recruiting

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2